Pontocerebellar hypoplasia type 5

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:166068OMIM:610204
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Pontocerebellar hypoplasia type 5 (PCH5) is an extremely rare and severe neurodegenerative disorder characterized by pronounced underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. PCH5 is distinguished from other forms of pontocerebellar hypoplasia by its prenatal onset with fetal seizures, and it presents at birth with severe encephalopathy, profound intellectual disability, and seizures that are often intractable. Affected infants typically exhibit microcephaly, spasticity, and minimal voluntary movement. The condition has been associated with mutations in the TSEN54 gene, which encodes a subunit of the tRNA splicing endonuclease complex, linking it molecularly to several other PCH subtypes. Clinically, PCH5 affects the central nervous system profoundly. Neuroimaging reveals severe cerebellar and pontine hypoplasia, with a characteristic "dragonfly" or "butterfly" appearance of the cerebellum on MRI due to preferential involvement of the cerebellar hemispheres relative to the vermis. Affected neonates may present with respiratory difficulties, feeding problems, and opisthotonus. Fetal seizures, which may be detected prenatally, are a hallmark feature that helps distinguish PCH5 from other PCH subtypes. The prognosis is extremely poor, with most affected individuals dying in the neonatal period or early infancy. There is currently no curative treatment for PCH5. Management is entirely supportive and palliative, focusing on seizure control with anticonvulsant medications, nutritional support (often via nasogastric or gastrostomy tube feeding), respiratory support, and physical therapy. Genetic counseling is recommended for affected families. Research into the molecular mechanisms underlying tRNA splicing endonuclease complex dysfunction continues, but no disease-modifying therapies are available at this time.

Also known as:

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Pontocerebellar hypoplasia type 5.

View clinical trials →

No actively recruiting trials found for Pontocerebellar hypoplasia type 5 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Pontocerebellar hypoplasia type 5 community →

Specialists

1 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Pontocerebellar hypoplasia type 5.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Pontocerebellar hypoplasia type 5Forum →

No community posts yet. Be the first to share your experience with Pontocerebellar hypoplasia type 5.

Start the conversation →

Latest news about Pontocerebellar hypoplasia type 5

No recent news articles for Pontocerebellar hypoplasia type 5.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Pontocerebellar hypoplasia type 5

What is Pontocerebellar hypoplasia type 5?

Pontocerebellar hypoplasia type 5 (PCH5) is an extremely rare and severe neurodegenerative disorder characterized by pronounced underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. PCH5 is distinguished from other forms of pontocerebellar hypoplasia by its prenatal onset with fetal seizures, and it presents at birth with severe encephalopathy, profound intellectual disability, and seizures that are often intractable. Affected infants typically exhibit microcephaly, spasticity

How is Pontocerebellar hypoplasia type 5 inherited?

Pontocerebellar hypoplasia type 5 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Pontocerebellar hypoplasia type 5 typically begin?

Typical onset of Pontocerebellar hypoplasia type 5 is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Pontocerebellar hypoplasia type 5?

1 specialists and care centers treating Pontocerebellar hypoplasia type 5 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.